Wave Life Sciences Receives US Orphan Drug and Rare Pediatric Disease Designations for WVE-210201 | DuchenneXchange

welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Wave Life Sciences Receives US Orphan Drug and Rare Pediatric Disease Designations for WVE-210201


Wave Life Sciences Ltd., a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted both orphan drug designation and rare pediatric disease designation for WVE-210201 for the treatment of Duchenne muscular dystrophy (DMD). The European Commission previously granted orphan drug designation for WVE-210201 in July 2018.

https://www.duchennexchange.org/wp-content/uploads/2018/08/Wave-Logo-Swoosh-01-005.png